Evidence-based, cost-effective risk stratification and management after myocardial infarction

被引:36
作者
Deedwania, PC
Amsterdam, EA
Vagelos, RH
Gregoratos, G
Kappagoda, T
Viejo, A
Caso, R
Chatterjee, K
Dennish, G
Elkayam, U
Fonarow, G
Golden, P
Goldschlager, N
Kane, JP
Karliner, JS
Kloner, RM
Shabatei, R
Berman, D
Superko, B
机构
[1] UNIV CALIF DAVIS, SCH MED, DAVIS, CA 95616 USA
[2] STANFORD UNIV, MED CTR, DIV CARDIOVASC MED, PALO ALTO, CA 94304 USA
关键词
D O I
10.1001/archinte.157.3.273
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Current management of patients after an acute myocardial infarction (AMI) reflects a variety of approaches ranging from conservative to aggressive. Although each method is appropriate in certain subgroups, their application frequently lacks a scientific basis. Current, clinically relevant, evidence-based practice guidelines are needed for secondary prevention for survivors after an AMI. To meet this need, the California Cardiology Working Group was assembled to evaluate the available data from clinical trials and other published studies and develop evidence-based, cost-effective guidelines for clinicians to use as a basis for patient management after an AMI. The group consisted of 18 members, including cardiologists from academic institutions and physicians working in cardiac intensive care, private practices, and managed care settings, representing a broad spectrum of expertise pertaining to patients who have had an AMI. The members had expertise in cardiac intensive care, interventional cardiology, nuclear cardiology, lipid disorders, echocardiography, and cardiac rehabilitation. The intended audience for these practice guidelines includes all physicians who treat survivors of MI, A literature review of all relevant clinical trials and other published data about the natural history after AMI and the effects of current therapeutic modalities are discussed herein. Case histories served as models for application of the literature-based data. The recommendations for management were reached by consensus vote based on the scientific evidence. When more than 1 management option applied, this was recognized in the recommendations. The recommendations accompany the text.
引用
收藏
页码:273 / 280
页数:8
相关论文
共 47 条
[1]  
*AM HEART ASS, 1995, HEART STROK FACTS 19
[2]   THE EFFECT OF THE ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR ZOFENOPRIL ON MORTALITY AND MORBIDITY AFTER ANTERIOR MYOCARDIAL-INFARCTION [J].
AMBROSIONI, E ;
BORGHI, C ;
MAGNANI, B .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (02) :80-85
[3]   NONPHARMACOLOGIC THERAPY FOR CORONARY-ARTERY ATHEROSCLEROSIS - RESULTS OF PRIMARY AND SECONDARY PREVENTION TRIALS [J].
AMSTERDAM, EA ;
HYSON, D ;
KAPPAGODA, CT .
AMERICAN HEART JOURNAL, 1994, 128 (06) :1344-1352
[4]  
[Anonymous], 1988, BRIT MED J, V296, P320
[5]  
BALL SG, 1993, LANCET, V342, P821
[6]  
BALL SG, 1994, BRIT HEART J, V72, pS70
[7]   THE RELATIONSHIPS AMONG VENTRICULAR ARRHYTHMIAS, LEFT-VENTRICULAR DYSFUNCTION, AND MORTALITY IN THE 2 YEARS AFTER MYOCARDIAL-INFARCTION [J].
BIGGER, JT ;
FLEISS, JL ;
KLEIGER, R ;
MILLER, JP ;
ROLNITZKY, LM .
CIRCULATION, 1984, 69 (02) :250-258
[8]   15 YEAR MORTALITY IN CORONARY DRUG PROJECT PATIENTS - LONG-TERM BENEFIT WITH NIACIN [J].
CANNER, PL ;
BERGE, KG ;
WENGER, NK ;
STAMLER, J ;
FRIEDMAN, L ;
PRINEAS, RJ ;
FRIEDEWALD, W .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1986, 8 (06) :1245-1255
[9]  
CONNOLLY DC, 1983, MAYO CLIN PROC, V58, P249
[10]   IDENTIFICATION AND TREATMENT OF LOW-RISK PATIENTS AFTER ACUTE MYOCARDIAL-INFARCTION AND CORONARY-ARTERY BYPASS GRAFT-SURGERY [J].
DEBUSK, RF ;
BLOMQVIST, CG ;
KOUCHOUKOS, NT ;
LUEPKER, RV ;
MILLER, HS ;
MOSS, AJ ;
POLLOCK, ML ;
REEVES, TJ ;
SELVESTER, RH ;
STASON, WB ;
WAGNER, GS ;
WILLMAN, VL .
NEW ENGLAND JOURNAL OF MEDICINE, 1986, 314 (03) :161-166